Lupin launches partnership program to expand global reach of PrecisionSphere injectable platform
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets are indicated for the treatment of human immunodeficiency virus infection in adults and pediatric patients weighing at least 25 kg
Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
The company has received approval from DCGI to begin patient enrolment and dosing in the country
Subscribe To Our Newsletter & Stay Updated